Scottsdale 1/22/2016 8:00:00 PM
News / Stocks

QualityStocks News - Nutra Pharma (NPHC) Offers a Suite of Pain Management Remedies

QualityStocks would like to highlight Nutra Pharma Corp. (OTCQB: NPHC), a biotech company working in collaboration with its subsidiaries to develop an innovative pipeline of biopharmaceutical products for the management of neurological disorders, cancer, autoimmune, and infectious diseases. At the core of Nutra Pharma’s intellectual property is a unique platform for extracting neurotoxins from Asian cobra venom and transforming them into non-toxic therapeutics.

In the company’s news:

When someone is in pain, they cannot concentrate on anything other than how to alleviate that pain as quickly as possible, and many times, Tylenol just isn’t enough. The pain associated with injury and surgery is unbearable at times, but many people are understandably cautious about getting prescription narcotics from their doctors because of the obvious habit-forming, addictive risks associated with these medications.

Nutra-Pharma Corp. (OTCQB: NPHC) offers a suitable substitute to these potentially dangerous medications with its Nyloxin product – an all-natural product aimed at treating moderate to severe chronic pain. Chronic pain is defined as pain that lasts longer than three months and may be related to certain medical conditions including diabetes, arthritis, migraines, fibromyalgia, cancer, shingles, sciatica, and previous trauma or injury.

Nyloxin is available over the counter and comes in two strengths and three forms, conditional on what is more convenient and applicable to the person in need – an oral spray, a roll-on and a topical gel. This makes choosing your remedy much easier, because some people are wary of the time it takes for pills to work and would rather have a topical application medication to go right to the source of the pain.

Nyloxin is equivalent to 300 doses of aspirin and about 1/30 of a dose of morphine. So, you have a supremely effective method of instant pain relief, literally, in the palm of your hand that has none of the addictive ramifications of morphine. Substituting an all-natural form of pain relief (Nyloxin is derived from cobra venom) for habit forming narcotics or some lower strength over the counter competitors makes more sense for treating pain in an effective, time oriented manner.

Nyloxin is also becoming available all over the world, according to a recent letter to shareholders from Nutra Pharma CEO Rik J. Deitsch. The company announced that it has received acceptance for Nyloxin from CPAM – the medical authority in China – paving the way for distribution in the world’s fastest growing consumer market. Also, Nutra Phama announced its plans to distribute Nyloxin in Canada.

About QualityStocks

QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.

To sign up for The QualityStocks Daily Newsletter, please visit  

To connect with QualityStocks via Facebook, please visit

To connect with QualityStocks via Twitter, please visit

Please read FULL disclaimer on the QualityStocks website:   

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.